▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Max Macaluso

TMFMassimo

Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.

Recent Articles by Max Macaluso

Sep 23, 2013 by Max Macaluso, Dave Williamson, and Alison Southwick

Market Checkup: September 23

The Motley Fool's health-care show, Market Checkup, for September 23.

Sep 20, 2013 by Max Macaluso and Dave Williamson

Groundbreaking Diabetes Drug Headlines Approval Bonanza

The EU's CHMP issued a positive opinion for Johnson & Johnson's diabetes drug Invokana. Who will the company face off against across the pond?

Sep 20, 2013 by Max Macaluso

Prosensa Plunges 70% as Sarepta Soars

How today's clinical trial news affects biotech company Prosensa, its big pharma partner GlaxoSmithKline, and rival Sarepta.

Sep 19, 2013 by Max Macaluso and Dave Williamson

AstraZeneca: Lost Stock or Cheap Turnaround?

Can this big pharma company return to growth?

Sep 19, 2013 by Max Macaluso, Dave Williamson, and Alison Southwick

Market Checkup: September 19, 2013

The Motley Fool's health-care show for September 19.

Sep 19, 2013 by Max Macaluso, Dave Williamson, and Alison Southwick

Google's Next Project: Curing Diseases?

Is Google funding what could become the most revolutionary biotech company in history?

Sep 19, 2013 by Max Macaluso and Dave Williamson

1 Big Pharma Leaps Past Hurdle

Sanofi won EU approval for MS drug Lemtrada this week.

Sep 18, 2013 by Max Macaluso and Dave Williamson

Do Fish Oil Drugmakers Need to Worry About Generics?

A recent court ruling might mean generic Lovaza will hit the market in the near future.

Sep 18, 2013 by Max Macaluso and Dave Williamson

This Dividend Stock's Secret Weapon?

Investors should take a closer look at AbbVie's drug development pipeline.

Sep 18, 2013 by Max Macaluso, Dave Williamson, and Alison Southwick

Market Checkup: Sept. 18, 2013

Today's health-care headlines.

Sep 18, 2013 by Max Macaluso and Dave Williamson

A New Combination Treatment for Big Pharma GlaxoSmithKline?

Glaxo's melanoma cocktail gets priority review from Food and Drug Administration.

Sep 18, 2013 by Max Macaluso and Dave Williamson

A Big Boost or False Hope For This Biotech?

Dendreon's Provenge received approval in the EU. Is this a major opportunity for the struggling biotech?

Sep 18, 2013 by Max Macaluso and Dave Williamson

Market Checkup: September 17, 2013

Decisions from the EU's regulatory agency and a dividend stock to watch.

Sep 17, 2013 by Max Macaluso and Dave Williamson

What's Holding This Big Pharma Back?

The reasons behind AstraZeneca's lackluster performance.

Sep 17, 2013 by Max Macaluso and Dave Williamson

Can Teva Turn Things Around?

The market may not be enthusiastic about Teva's stock, but what can the company do to boost investor confidence?

Sep 17, 2013 by Max Macaluso and Dave Williamson

1 Dividend Stock for Your Watchlist?

What makes this health-care company a dividend stock to watch?

Sep 17, 2013 by Max Macaluso and Dave Williamson

1 Biotech Going International

What does this EU approval mean for Raptor?

Sep 17, 2013 by Max Macaluso and Dave Williamson

Market Checkup: Sept. 16, 2013

The Motley Fool's health-care show Market Checkup for September 16, 2013.

Sep 17, 2013 by Max Macaluso and Dave Williamson

Is Another Biotech Buyout on the Horizon?

What makes ViroPharma an attractive target for big pharma Sanofi and orphan drug specialist Shire?

Sep 17, 2013 by Max Macaluso and Dave Williamson

Patent Expirations AbbVie Investors Need to Watch

A look at AbbVie's most important patent expirations.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services